Schedule 13G ownership disclosure

Aclaris Therapeutics Inc

Common Stock, $0.00001 par value · CUSIP: 00461U105

Event date: 2026-03-09

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Deep Track Capital, LP

    Shares: 9,345,000.00 · Class: 7.0%

  • Deep Track Biotechnology Master Fund, Ltd.

    Shares: 9,345,000.00 · Class: 7.0%

  • David Kroin

    Shares: 9,345,000.00 · Class: 7.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001172661-26-001355
Form type
SCHEDULE 13G
Filer
Aclaris Therapeutics, Inc.
CIK
CIK 1557746
Filed
Mar 17, 2026
Reporting period
Mar 09, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub